Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/519 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2684615

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or compositions.

L'invention concerne, dans de nombreux modes de réalisation, une nouvelle classe de composés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs des kinases dépendants des cyclines, des méthodes de préparation de ces composés, des compositions contenant au moins un de ces composés, des méthodes de préparation de formulations pharmaceutiques comprenant au moins un de ces composés, et des méthodes utilisant ces composés ou compositions pour le traitement, la prévention, l'inhibition ou l'amélioration d'une ou de plusieurs maladies associées aux CDK.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1372385

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.